RxDoctor Payments Data

Steven Siskind, MD

Cardiovascular Disease · Manhasset, NYNPI 1376542944

Payments from drug & device makers

$1,780in general payments, 2019–2025

Across 66 payments — averaging $26.97 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$582
  • Novartis$418
  • Boehringer Ingelheim$176
  • E.r. Squibb & Sons, L.L.C.$159
  • Medtronic$122
  • Amgen$49
  • plus $274 from 10 others

What the payments were for

  • Food & beverage$1,76699%
  • Education$141%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,780 in reported general payments places this provider in the 50th percentile of 2,302 cardiovascular disease providers in New York.

See all cardiovascular disease providers in New York

Medicare billing

Part B allowed, 2024
$278,086
Medicare patients
674
Services billed
3,421

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban320$374,030
EntrestoSacubitril/Valsartan81$110,654
XareltoRivaroxaban75$94,734
JardianceEmpagliflozin38$49,445
MounjaroTirzepatide30$34,904
OzempicSemaglutide27$34,804
BrilintaTicagrelor31$29,143
Repatha SureclickEvolocumab24$22,161
MultaqDronedarone Hcl12$14,293
NexlizetBempedoic Acid/Ezetimibe16$9,956
Metoprolol Succinate431$7,912
Trelegy ElliptaFluticasone/Umeclidin/Vilanter12$7,490
Atorvastatin Calcium351$3,415
Rosuvastatin Calcium190$2,647
Clonidine19$1,879

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$16$374,030320 claims
NovartisEntresto$418$110,65481 claims
Johnson & JohnsonXarelto$582$94,73475 claims
Boehringer IngelheimJardiance$176$49,44538 claims
AstraZenecaBrilinta$43$29,14331 claims
Sanofi-aventis U.S. LLCMultaq$40$14,29312 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 2,302 cardiovascular disease providers in New York.

Other cardiovascular disease in Manhasset

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →